<DOC>
	<DOCNO>NCT00001996</DOCNO>
	<brief_summary>To compare safety atovaquone ( 566C80 ) intravenous ( IV ) pentamidine treatment mild moderate Pneumocystis carinii pneumonia ( PCP ) AIDS patient intolerant therapy trimethoprim / sulfamethoxazole ( TMP / SMX ) compare incidence premature discontinuation therapy due toxicity . To compare efficacy 566C80 intravenous ( IV ) pentamidine treatment mild moderate PCP population .</brief_summary>
	<brief_title>A Phase II Open Randomized Comparison 566C80 Pentamidine Isethionate Treatment Pneumocystis Carinii Pneumonia AIDS Patients Who Are Intolerant Trimethoprim / Sulfamethoxazole</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Pneumocystis</mesh_term>
	<mesh_term>Sulfamethoxazole</mesh_term>
	<mesh_term>Trimethoprim</mesh_term>
	<mesh_term>Pentamidine</mesh_term>
	<mesh_term>Atovaquone</mesh_term>
	<mesh_term>Trimethoprim , Sulfamethoxazole Drug Combination</mesh_term>
	<criteria>Inclusion Criteria Patients must follow : History , currently experience , intolerance TMP / SMX , another sulfonamide , require discontinuation therapy . Pneumocystis carinii pneumonia ( PCP ) . Willing able give inform consent . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude . Malabsorption disorder vomit would , judgement investigator , potentially limit retention absorption oral therapy . Concurrent bacterial , fungal , viral pneumonitis , pulmonary Kaposi 's sarcoma , concurrent illness , chronic pulmonary disease , investigator 's opinion , would make interpretation drug efficacy difficult . Present occurrence abnormal prolongation QT interval standard , 12 lead EKG . Concurrent Medication : Excluded : Drugs potential antipneumocystis effect ( eg : sulfonamide , dapsone , trimethoprim , dihydrofolate reductase ( DHFR ) inhibitor , primaquine , clindamycin , sulfonylureas ) . Ganciclovir . Zidovudine . Investigational agent include antiretroviral agent ( ddI , ddC , etc. ) . Patients receive drug prior entry must discontinue use therapy phase ( 21 day ) trial . Corticosteroids ( except replacement therapy ) 21 day treatment period ( Strata A C Patients ) . Class 1A antiarrhythmic ( ie : quinidine , procainamide , disopyramide ) . Patients follow exclude : Judged investigator impend respiratory failure . Known intolerance parenteral pentamidine isethionate , therapeutic failure treatment current episode PCP . Significant psychosis emotional disorder , investigator 's opinion , would preclude patient adhere protocol . Inability unwillingness take medication orally food . Prior document glucose6phosphate dehydrogenase ( G6PD ) deficiency . History , present occurrence , abnormal prolongation QT interval standard , 12 lead EKG . Termination FDA 053A due toxicity . For patient enter historic intolerance criterion ( Groups A B ) , prior therapy episode PCP exclusion . Prior Medication : Excluded : Treatment within 4 week entry prior episode PCP . For patient enter historic intolerance criterion ( Groups A B ) , prior therapy episode PCP exclusion . Required : Adjuvant prednisone patient enrol Strata B D .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 1992</verification_date>
	<keyword>Trimethoprim-Sulfamethoxazole Combination</keyword>
	<keyword>Pneumonia , Pneumocystis carinii</keyword>
	<keyword>Pentamidine</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>atovaquone</keyword>
</DOC>